Your session is about to expire
← Back to Search
Personalized Vaccine + TTFields for Glioblastoma
Study Summary
This trial will use a vaccine, based on a patient's unique tumor mutations, in combination with standard care and a new cancer treatment called TTFields, to treat glioblastoma. The goal is to see if the combination is safe and well tolerated.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have HIV/AIDS or chronic hepatitis B/C.I am 18 years old or older.My diagnosis is Grade IV brain cancer (GBM).I am undergoing surgery to remove as much of the tumor as possible, followed by radiation therapy with Temozolomide.My condition hasn't worsened after chemotherapy and radiation.You are expected to live for at least another four months.My condition has worsened recently.You have had an allergic reaction to Temozolomide in the past.My cancer is located below the tentorium in my brain or is present in multiple areas.You are currently taking any other experimental drugs for research purposes.I am mentally capable of understanding and agreeing to the trial.I have a condition that weakens my immune system.My bone marrow is functioning well.My first vaccine dose is scheduled 4-8 weeks after my last Temozolomide or radiotherapy dose.My blood, liver, and kidney tests are normal and were done within the last 14 days.I had cancer before and was treated for it within the last year.I can take care of myself and perform daily activities.I am on a stable dose of Dexamethasone, 4mg or less daily.I have an autoimmune disease, but it's not vitiligo.
- Group 1: Mutation-derived tumor vaccine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA sanctioned Tumor Treating Fields for therapeutic usage?
"The safety of Tumor Treating Fields is estimated to be a 1 on our scale, as this is just an initial Phase 1 trial with limited information demonstrating its efficacy and security."
Is enrollment for this trial still open to the public?
"As indicated on clinicaltrials.gov, this research program does not require participants at present. Originally listed online on March 1st 2018 and last updated July 19th 2022, it is one of 442 other studies currently recruiting patients for their respective trials."
Share this study with friends
Copy Link
Messenger